US EditionPublished • loading... • Updated
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
- On May 7, 2025, SCG Cell Therapy revealed late-breaking Phase 1 results in Singapore for SCG101, a personalized TCR-T cell treatment targeting HBV, tested in individuals suffering from advanced liver cancer associated with chronic hepatitis B infection.
- This trial addressed a significant clinical need due to the high global burden of HBV infection and its role in causing advanced HCC with poor prognosis and limited treatment options.
- Following a single infusion, SCG101 induced a rapid and sustained serum HBsAg decline in all patients, with 94% achieving a 1.0–4.6 log reduction within 28 days and 47% showing measurable tumor regression amid a heavily pre-treated cohort.
- Treatment was generally well tolerated, with transient alanine aminotransferase elevation in 94% of patients resolving within 14 days, consistent with the therapy’s cytolytic mechanism, as noted by experts and company leadership.
- These data validate SCG101 as the first TCR-T therapy to show virologic clearance and tumor response in HBV-related HCC, supporting its further clinical development as a potential new immunotherapeutic option for this condition.
Insights by Ground AI
61 Articles
61 Articles
The Berkshire Eagle+58 Reposted by 58 other sources
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous…
Coverage Details
Total News Sources61
Leaning Left6Leaning Right7Center20Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 18%
C 61%
R 21%
Factuality
To view factuality data please Upgrade to Premium
